Loading patent…
AssigneeWarner-Lambert Company
InventorsStephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, II, Aeri Park, Petinka Ivanova Vlahova
Estimating the term…
Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
A crystalline Form V atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form VI atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form VII atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form VIII atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form IX atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form X atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XI atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XII atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XIII atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XIV atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XV atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XVI atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XVII atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XVIII atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
A crystalline Form XIX atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuKα radiation:
Dependencies are inferred from the claim text.